Is overactive bladder a risk factor for erectile dysfunction? A cross-sectional study

Abstract

Aim: Erectile dysfunction (ED) is a sexual dysfunction characterized by the inability to achieve or maintain penile erection during sexual activity. Many risk factors have been identified in ED-related epidemiological studies. In experimental studies, a relationship is thought to exist between Overactive Bladder (OAB) and ED. We investigated the relationship between OAB and ED, its clinical reflections, and the odds ratio of OAB for ED. Methods: We conducted this cross-sectional prospective study between January-July 2020. Sixty patients referred to the urology outpatient clinic with complaints of OAB (Group 1) and 66 patients without urological complaints (Group 2) were included in the study. Patients’ erectile functions were evaluated with the IIEF-5 form. OAB was evaluated with the OAB-V8 form. Results: The groups were similar in terms of age, body mass index, comorbidity, and smoking status. IIEF-5 scores were higher in Group 2 [20.52 (3.51)] compared to Group 1 [18.17 (5.46)] (P=0.036). Correlation analysis between IEF-5 and OAB-V8 scores revealed a negative correlation; it was observed that the IIEF-5 score decreased as the OAB-V8 score increased (r=-0.260, P=0.045). The odds ratio of decreasing IIEF-5 score with each 1-unit increase of OAB-V8 score was 0.164 (P=0.04). It was observed that the patients diagnosed with OAB had lower IIEF-5 scores when they had nocturia. Conclusion: OAB is a risk factor for ED. The presence of nocturia symptoms is remarkable for ED in OAB patients. The effect of OAB should not be ignored in the treatment of ED.

Keywords

• Erectile Dysfunction
• IIEF-5
• ; OAB
• Overactive Bladder

Aşırı aktif mesane erektil disfonksiyon için bir risk faktörü müdür? Kesitsel çalışma

Abstract

Amaç: Erektil disfonksiyon (ED), cinsel aktivite sırasında penis ereksiyonunun sağlanamaması veya sürdürülememesi ile karakterize bir cinsel işlev bozukluğudur. ED ile ilişkili epidemiyolojik çalışmalarda birçok risk faktörü tanımlanmıştır. Deneysel çalışmalarda Aşırı Aktif Mesane (OAB) ile ED arasında bir ilişki olduğu düşünülmektedir. Bu çalışmamızda OAB ve ED arasındaki ilişkiyi, klinik yansımalarını ve ED için OAB'nin risk oranını araştırmayı amaçladık. Yöntemler: Bu kesitsel çalışmayı Ocak 2020 ve Temmuz 2020 arasında gerçekleştirdik. OAB (Grup 1) şikayetleri ile üroloji polikliniğine başvuran 60 hasta ve ürolojik şikayeti olmayan 66 hasta (Grup 2) çalışmaya dahil edildi. Hastaların erektil fonksiyonları IIEF-5 formu ile aşırı aktif mesane sorgulaması OAB-V8 formu ile değerlendirildi. Bulgular: Gruplar yaş, vücut kitle indeksi, komorbidite ve sigara içme durumu açısından benzerdi. IIEF-5 skorları Grup 2'de [20,52 (3,51)] Grup-1'e [18,17 (5,46)] göre daha yüksek bulundu (P=0,036). IEF-5 score ve OAB-V8 score arasında yapılan korelasyon analizinde negatif korelasyon saptandı; OAB-V8 skoru arttıkça IIEF-5 skorunun düştüğü gözlendi (r -0,260, P=0,045). OAB-V8 skorunun her 1 birim artışında IIEF-5 puanınında ki azalma risk oranı 0,164 olarak bulunmuştur (P=0.04). OAB tanısı alan hastalarda noktüri varlığında IIEF-5 skorlarının daha düşük olduğu gözlendi. Sonuç: OAB, ED için bir risk faktörüdür. Noktüri semptomlarının varlığı OAB hastalarında ED için dikkat çekicidir. ED tedavisinde OAB'nin etkisi göz ardı edilmemelidir.

Keywords

• Erektil Disfonksiyon
• IIEF-5
• OAB
• Aşırı Aktif Mesane

References

1. 1. Valiquette, L. A historical review of erectile dysfunction. The Canadian Journal of Urology. 2003;10(Suppl 1):7-11. PMID: 12625844
2. 2. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachusetts male aging study. Soc Sci Med 2000;51(5):771-8. doi:.10.1016/s0277-9536(00)00022-8
3. 3. Beutel ME, Weidner W, Brähler E. Epidemiology of sexual dysfunction in the male population. Andrologia. 2006;38(4):115-21. doi: 10.1111/j.1439-0272.2006.00730.x
4. 4. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017;3(4-5):352-63. doi: 10.1016/j.euf.2017.11.004
5. 5. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-78. doi: 10.1002/nau.10052
6. 6. Jiann BP. Dose Overactive Bladder (OAB) Type Affect the Strength of the Association between OAB and Erectile Dysfunction? J Sex Med. 2013;10:1187. doi: 10.1111/jsm.12053
7. 7. Liu RT, Chung MS, Chuang YC, Lee JJ, Lee WC, Chang HW, et al. The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes. J Sex Med 2012;9:1913-22. doi: 10.1111/j.1743-6109.2012.02738.x
8. 8. Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: Results from EpiLUTS. J Sex Med 2011;8:1603-15. doi: 10.1111/j.1743-6109.2011.02250.x

9. 9. Oliveira P, Castro NM, Muniz AL, Tanajura D, Brandão JC, Porto AF, et al. Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. Urology. 2010;75(5):1100-3. doi: 10.1016/j.urology.2009.11.041
10. 10. Debra E. Irwin, Ian Milsom, Kate Reilly, Steinar Hunskaar, Zoe Kopp, Sender Herschorn, et al. Overactive Bladder Is Associated with Erectile Dysfunction and Reduced Sexual Quality of Life in Men. J Sex Med 2008;5:2904-10 doi: 10.1111/j.1743-6109.2008.01000.x
11. 11. Zumrutbas AE, Bozkurt AI, Tas E, Acar CI, Alkis O, Coban K, et al. Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western Turkey: results of a population-based survey. Int J Urol. 2014;21(10):1027-33. doi: 10.1111/iju.12519
12. 12. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14. doi: 10.1016/j.eururo.2006.09.019
13. 13. Quek KF. Factors affecting health-related quality of life among patients with lower urinary tract symptoms. Int J Urol 2005;12:1032-6. doi: 10.1111/j.1442-2042.2005.01198.x
14. 14. de Oliveira MG, Rojas-Moscoso JA, Bertollotto GM, Candido TZ, Kiguti LRA, Pupo AS, et al. Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response. Eur J Pharmacol. 2019;5;858:172447. doi: 10.1016/j.ejphar.2019.172447
15. 15. Dhruva A, Hamsavardhini VK, Kamatham S, Kataria A, Kumar A, Shanthi M, et al. Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle. Int J Appl Basic Med Res. 2019;9(4):231-5. doi: 10.4103/ijabmr.IJABMR_339_18.
16. 16. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abrigged, 5-item version of the International Ondex of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfuntion. International Journal of Impotence Research. 1999;11(6):319-26. doi: 10.1038/sj.ijir.3900472
17. 17. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, et al. Translating overactive bladder questionnaries in 14 languages. Urology. 2006;67:536. doi: 10.1016/j.urology.2005.09.035
18. 18. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637-49. doi: 10.1016/j.eururo.2003.08.015
19. 19. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int. 2005;96:1339-54. doi: 10.1111/j.1464-410X.2005.05831.x
20. 20. Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl. 2006;52:155-62. doi: 10.1080/01485010500379871
21. 21. Bang-Ping Jiann. Dose Overactive Bladder (OAB) Type Affect the Strength of the Association between OAB and Erectile Dysfunction? J Sex Med. 2013;10:1187. doi: 10.1111/jsm.12053
22. 22. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Import Res. 2000;12:305-11. doi: 10.1038/sj.ijir.3900622
23. 23. Amano T, Earle C, Imao T, Takemae K. Are urge inkontinence and aging risk factors of erectile dysfunction in patients with male lower urinary tract symptoms? Aging Male. 2016;19(1):54-7. doi: 10.3109/13685538.2015.1103219.
24. 24. Ponholzer A, Temml Ch, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47(1):80-6. doi: 10.1016/j.eururo.2004.08.017
25. 25. Hajebrahimi S, Azaripour A, Sadeghi-Bazargani H. Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med. 2008;5:2880-5. doi: 10.1111/j.1743- 6109.2008.00976.x
26. 26. Rogers RG, Omotosho T, Bachmann G, Sun F, Morrow JD. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:381-5. doi: 10.1007/s00192-008-0782-9
27. 27. Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006;195(6):1730-5. doi: 10.1016/j.ajog.2006.08.013